Intellia Therapeutics Inc expected to post a loss of $1.33 a share - Earnings Preview

INTELLIA THERAPEUTICS

25/02/2025 13:39

Intellia Therapeutics Inc NTLA.OQ NTLA.O is expected to show a rise in quarterly revenue when it reports  results on February 27 for the period ending December 31 2024

The Cambridge Massachusetts-based  company is expected to report a 545.1% decrease in revenue to $8.532 million from $-1.92 million a year ago, according to the mean estimate from 21 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Intellia Therapeutics Inc is for a loss of $1.33 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 20 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Intellia Therapeutics Inc is $46.00​, above​ its last closing price of $11.51. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-1.41
-1.38
-1.34
Beat
3.2
Jun. 30 2024
-1.25
-1.23
-1.52
Missed
-23.4
Mar. 31 2024
-1.39
-1.38
-1.12
Beat
18.8​
Dec. 31 2023
-1.45
-1.45
-1.46
Missed
-0.7
​​Sep. 30 2023
-1.49
-1.50
-1.38
Beat
7.9
Jun. 30 2023
-1.30
-1.32
-1.40
Missed
-6​
Mar. 31 2023
-1.41
-1.40
-1.17
Beat
16.4
Dec. 31 2022
-1.41
-1.39
-1.40
Missed
-0.5

This summary was machine generated February 25 at 13:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)